GUT: Helicobacter pylori infection has an adverse effect on the efficacy of cancer immunotherapy

Immune checkpoint inhibitors (ICIs) are designed to rejuvenate the immune system to fight cancer cells
.

However, despite the unprecedented results, most patients do not respond well to ICI, and this phenomenon is related to some individual factors and drug resistance, such as the composition of the intestinal microbiota and the tumor immune environment

Immune checkpoint inhibitors (ICIs) are designed to rejuvenate the immune system to fight cancer cells

 

However, in published studies, no common bacteria have been clearly identified as key indicators and/or modulators of the ICI response
.

Helicobacter pylori (H.

Infect

 

 

To this end, the researchers used mouse models to evaluate whether immune checkpoint inhibitors or vaccine-based immunotherapy can effectively reduce tumor volume in mice infected with Helicobacter pylori
.

In humans, the researchers evaluated the correlation between Helicobacter pylori seropositivity and the efficacy of programmed cell death protein 1 (PD-1) blocking therapy in patients with non-small cell lung cancer ( NSCLC )

NSCLC

 

The results of the study showed that in mice implanted with MC38 colon adenocarcinoma or B16-OVA melanoma cells, uninfected mice treated with anti-cytotoxic T lymphocyte-associated protein 4 and/or programmed death ligand 1 or anti-cancer vaccines The tumor volume of mice was significantly smaller than those of infected mice
.

In the tumors of infected mice treated with cancer immunotherapy, the number and activation of tumor-specific CD8 + T cells decreased, regardless of the composition of the gut microbiome

Figure: The impact of Helicobacter pylori on cancer treatment

This study reveals for the first time that the gastric microbiota affects the response to cancer immunotherapy, and confirms that Helicobacter pylori serology will become a powerful tool for personalized cancer immunotherapy treatment
.

This study reveals for the first time that the gastric microbiota affects the response to cancer immunotherapy, and confirms that Helicobacter pylori serology will become a powerful tool for personalized cancer immunotherapy treatment
.

 

 

Original source:

Paul Oster.

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
Leave a message here